Intercept Pharma (ICPT) Tops Q3 EPS by 42c, Revenues Miss; Offers FY18 Revenue Guidance

Intercept Pharma (NASDAQ: ICPT) reported Q3 EPS of ($2.14), $0.42 better than the analyst estimate of ($2.56). Revenue for the quarter came in at $46.99 million versus the consensus estimate of $48.24 million.

“2018 has been an important year for Intercept as we have continued to make progress executing against our key strategic priorities in our Phase 3 NASH program and our PBC commercial efforts,” said Mark Pruzanski, M.D., President and Chief Executive Officer of Intercept. “We remain on track to report top line data from the Phase 3 REGENERATE trial in the first half of 2019. We have also continued to advance our efforts to bring Ocaliva to eligible PBC patients in need and believe that we are well positioned to drive growth and capitalize on this sizeable market opportunity.”

GUIDANCE:

Intercept Pharma sees Q4 2018 revenue of $170-185 million, versus the consensus of $181.84 million.

For earnings history and earnings-related data on Intercept Pharma (ICPT) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Rein Therapeutics Inc. (RNTX) Tops Q2 EPS by 39c
• Edible Garden AG (EDBL) Reports Q2 Loss of $18.79